Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study

Hepatitis

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study

Lancet Gastroenterol Hepatol.

Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, Ramji A, Chen CY, Tam E, Bae H, Ma X, Flaherty JF, Gaggar A, Lau A, Liu Y, Wu G, Suri V, Tan SK, Subramanian GM, Trinh H, Yoon SK, Agarwal K, Lim YS, Chan HLY

doi: 10.1016/S2468-1253(19)30421-2.

Hepatitis

Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study

Am J Gastroenterol.

Bzowej NH, Tran TT, Li R, Belle SH, Smith CI, Khalili M, Chung R, Tsai N, Terrault N, Hepatitis B Research Network (HBRN).

doi: 10.14309/ajg.

Gastrointestinal Cancer

Comparative Effectiveness of Entecavir vs Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: a Systematic Review and Meta-analysis

Hepatology.

Dave S, Park S, Murad MH, Barnard A, Prokop L, Adams LA, Singh S, Loomba R

doi: 10.1002/hep.31267.

Hepatitis

Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial

Am J Gastroenterol.

Yim HJ, Kim W, Ahn SH, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Um SH, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Han KH

doi: 10.14309/ajg.0000000000000605.

Hepatitis

Use of Hepatitis B Virus Core Related Antigen to Evaluate Natural History of Chronic Hepatitis B

J Gastroenterol Hepatol.

Chan HLY, Yasuda S, Wong GLH, Tada T, Chan CKM, Kumada T, Tse YK, Wong VWS, Toyoda H

doi: 10.1111/jgh.15058.

Hepatitis

Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials

Lancet Gastroenterol Hepatol.

Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos , Crans G, Flaherty J, Gaggar A, Marcellin P

doi: 10.1016/S2468-

Hepatitis

Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)

Gut.

Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, Feld JJ, Hansen BE, Janssen HLA

doi: 10.1136/gutjnl-2019-318981.

HepatitisHepatology

Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients

J Gastroenterol Hepatol

Kaneko S, Kurosaki M, Inada K, Kirino S, Hayakawa Y, Yamashita K, Osawa L, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N

doi: 10.1111/jgh.15563

Hepatitis

Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study

J Hepatol.

Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, Schwabe C, Dunbar PR

doi: 10.1016/j.jhep.

Related content

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study

Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study

Comparative Effectiveness of Entecavir vs Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: a Systematic Review and Meta-analysis

Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial

Use of Hepatitis B Virus Core Related Antigen to Evaluate Natural History of Chronic Hepatitis B

Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials

Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)

Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients

Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study